Year None202420232022202120202019201820172016 Date Latest Press Release May 3, 2024 Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals April 1, 2024 Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection January 18, 2024 Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan January 4, 2024 Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split November 9, 2023 Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update September 12, 2023 Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta August 14, 2023 Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update June 29, 2023 Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO June 28, 2023 Eiger BioPharmaceuticals to Host Business Update Call Tomorrow May 11, 2023 Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
